Aesthetic patients are bundling treatments

Today’s typical aesthetic patient is no longer presenting for a single, isolated treatment. Increasingly, they are building integrated routines – layering injectables, skincare, energy-based technologies and weight management therapies within the same appointment.

This shift is captured in market research company Qsight’s recent report, ‘What Patients Bundle Most: Unpacking Aesthetic Purchasing Trends’. Drawing on millions of point-of-sale transactions across nearly 4,000 US aesthetic practices and medspas, the report provides a real-time, evidence-based view of patient behaviour.

Powered by Qsight’s Sales Measurement Basket Analysis module, it reveals which services are most commonly combined, where patients are spending and what those patterns mean for both clinical and business growth strategy.

For medical aesthetic clinics, the findings reveal where patients are already creating bundled journeys – and where practices can meet them with smarter protocols and service combinations.

While the data is US-based, these findings are also relevant to Australian aesthetic clinics. Global branding, social media trends and shared consumer behaviours mean many of the same patterns are emerging here, too. Clinics paying attention to these shifts can stay ahead, offering more complete experiences and strengthening patient retention.

Twenty-five percent of all peel, microneedling and hydradermabrasion appointments also included a skincare purchase.

Injectables: still the core, not always the gateway

Injectables continue to anchor many patient visits. However, the way they are being consumed is changing. According to Qsight’s analysis, 53 percent of all HA dermal filler visits also include a neurotoxin treatment and 39 percent of biostimulatory filler visits also include a toxin procedure; conversely, only 13 percent of neurotoxin visits include filler procedures.

These figures highlight an asymmetry in bundling behaviour. While filler patients are likely to include toxin as part of their treatment plan, the reverse is occurring less frequently. This suggests a broader shift in how neurotoxin is positioned within the aesthetic patient’s routine, often as a maintenance treatment rather than a catalyst for further intervention.

For clinics, where toxin is the primary treatment, it may be more appropriate to pair with skin-quality services (eg, LED therapy, RF microneedling) or prescription skincare, rather than assuming readiness for volumising procedures. Conversely, filler appointments may present an opportunity to recommend full-face injectable harmonisation or additional device- based treatments as part of a more comprehensive plan.

‘Neurotoxins have long been a point of entry for aesthetics – however, with recent changes in dermal filler demand, there are opportunities emerging for practitioners to position other complementary services during neurotoxin visits,’ the authors write.

Skincare is no longer a side sale

One of the most striking insights in the report is how professional skincare has become central to the aesthetic visit. Twenty-five percent all peel, microneedling and hydradermabrasion appointments also include a skincare purchase. In those cases, skincare adds 30 to 45 percent more revenue per visit. In addition, the report found half of all professional skincare sales are made without any procedure during the same visit.

That last stat is especially interesting. It suggests many clinics are building retail programs that stand on their own. It highlights the opportunity for skincare consults, express facials or digital skincare assessments that keep patients engaged between treatments.

Weight-loss medications are changing the game

One of the most notable trends in the report is the rise of GLP- 1 weight-loss medications and how they are being bundled with traditional aesthetic services, at least in the US:

• 15 percent of all visits at clinics offering GLP-1s included a medication purchase.
• 10 percent of body-contouring patients also left with a GLP-1 prescription.

While the prescribing landscape for GLP-1s is more tightly regulated in Australia, the broader patient interest in weight management is increasingly relevant.

Clinics may encounter patients who are already using GLP-1s and seeking adjunctive therapies such as skin tightening and body contouring. So even if your clinic doesn’t prescribe GLP-1s, it’s worth preparing for these conversations. Establishing referral networks, updating consultation protocols and training staff in sensitive, evidence- based discussion of these topics may support both patient care and practice growth.

Qsight’s report offers a snapshot of how aesthetic patients are engaging with services today: what they choose, what they combine and how their behaviours are evolving. The data points to a consumer who is strategic, goal- oriented and increasingly expecting multi-modal care.

For clinics, understanding these patterns is important for delivering comprehensive care – and to meet patients with the treatment combinations they are already seeking.